

Switching to chlorthalidone compared to continuing hydrochlorothiazide: A new trial

Conclusion: Switching patients already taking hydrochlorothiazide for hypertension to chlorthalidone did not reduce their risk of adverse cardiovascular outcomes or risk of death after 2.4 years of follow-up.

The BC Provincial Academic Detailing (PAD) service began delivering the topic Hypertension in Primary Care in 2017. We noted an absence of completed trials directly comparing thiazides for cardiovascular and mortality outcomes, but we referred to an ongoing trial.¹ The trial was published in December 2022 (Diuretic Comparison Project trial) and compared people switched from hydrochlorothiazide to chlorthalidone for hypertension to those who stayed on hydrochlorothiazide.²

There were no differences in the primary outcome (non-fatal cardiovascular event or non-cancer death) between switching to an equipotent dose of chlorthalidone and continuing hydrochlorothiazide. Switching to chlorthalidone did result in an increase in allergic or adverse reactions and hypokalemia. However, in this trial's unblinded design, patients who switched to chlorthalidone underwent more laboratory monitoring, which may have resulted in the capture of more hypokalemia events. There were no significant differences between the two groups in all-cause mortality, serious adverse events, all-cause hospitalization, acute gout episodes, new onset diabetes, renal failure or hyponatremia.

| Diuretic Comparison Project trial summary: chlorthalidone compared to hydrochlorothiazide ² | | |
|--|--|---|
| Participants | 13,523 people age ≥ 65 (mean age: 72), 97% male, 77% White hypertension defined as SBP ≥ 120 mmHg (mean SBP: 139 mmHg) with an active prescription for hydrochlorothiazide 87% taking additional antihypertensives | |
| Intervention | switch to chlorthalidone 12.5 mg or 25 mg once a day (median dose: 12.3 mg) | |
| Comparator | continue hydrochlorothiazide 25 mg or 50 mg once a day (median dose: 23 mg) | |
| Outcomes | non-fatal cardiovascular event or non-cancer death | HR 1.04 (95%CI 0.94 to 1.16) |
| | death from any cause | HR 1.00 (95%CI 0.87 to 1.13) |
| | new allergic or adverse reaction to diuretic | HR 5.23 (95%CI 3.28 to 8.35) absolute risk increase: 1.3% |
| | hypokalemia | HR 1.38 (95%CI 1.19 to 1.60) absolute risk increase: 1.6% |
| Study Design | pragmatic open-label trial design, median follow-up 2.4 years primary care electronic health records in the Veterans Affairs Healthcare System (United States) | |

In B.C., both chlorthalidone and hydrochlorothiazide are regular benefit drugs on the BC PharmaCare formulary.

¹BC Provincial Academic Detailing service: Hypertension in Primary Care (November 2017) ²Ishani A et al Diuretic Comparison Project Working Group N Engl J Med 2022;387:2401-2410 (PMID: 36516076)

This document has been compiled for the British Columbia Ministry of Health's Pharmaceutical, Laboratory and Blood Services Division. The information contained in this document is intended for educational purposes only, and is not intended as a substitute for the advice or professional judgment of a health care professional. The information in this document is provided without any express or implied warranty regarding its content, and no party involved with the preparation of this document is responsible for any errors or omissions that may be contained herein, nor is any party involved with the preparation of this document responsible for the result obtained from the use of information in this document. Any use of this document will imply acknowledgement of this disclaimer and release the Province of British Columbia, its employees, agents and any party involved in the preparation of this document from any and all liability. Copyright © 2023, Province of British Columbia. All rights reserved.

BC Provincial Academic Detailing Service Email: PAD@gov.bc.ca Web: www.bcpad.ca